CL2018001720A1 - Crystalline polymorphic forms of obetolic acid - Google Patents

Crystalline polymorphic forms of obetolic acid

Info

Publication number
CL2018001720A1
CL2018001720A1 CL2018001720A CL2018001720A CL2018001720A1 CL 2018001720 A1 CL2018001720 A1 CL 2018001720A1 CL 2018001720 A CL2018001720 A CL 2018001720A CL 2018001720 A CL2018001720 A CL 2018001720A CL 2018001720 A1 CL2018001720 A1 CL 2018001720A1
Authority
CL
Chile
Prior art keywords
polymorphic forms
crystalline polymorphic
acid
obetolic
obetolic acid
Prior art date
Application number
CL2018001720A
Other languages
Spanish (es)
Inventor
André Steiner
Emilie Jolibois
Melissa Rewolinski
Ralf Gross
Emma Sharp
Fiona Dubas-Fisher
Alex Eberlin
Poulsen Heido Waenerlund
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55650649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018001720(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/979,005 external-priority patent/US9982008B2/en
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CL2018001720A1 publication Critical patent/CL2018001720A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Abstract

LA PRESENTE SOLICITUD SE REFIERE A LAS FORMAS CRISTALINAS A, D, F, G E L DEL ÁCIDO OBETICÓLICO. ESTAS FORMAS CRISTALINAS SON ÚTILES EN LA PRODUCCIÓN DE ÁCIDO OBETICÓLICO (EN PARTICULAR SU PURIFICACIÓN), EL CUAL ES UN FÁRMACO ÚTIL PARA EL TRATAMIENTO O LA PREVENCIÓN DE UNA ENFERMEDAD O AFECCIÓN MEDIADA POR FXR, ENFERMEDADES CARDIOVASCULARES O HEPATOPATÍA COLESTÁSICA, Y PARA REDUCIR EL COLESTEROL HDL, PARA REDUCIR LOS TRIGLICÉRIDOS EN UN MAMÍFERO O PARA INHIBIR LA FIBROSIS.THIS APPLICATION REFERS TO THE CRYSTAL FORMS A, D, F, G E L OF THE OBETICOLIC ACID. THESE CRYSTALLINE FORMS ARE USEFUL IN THE PRODUCTION OF OBETICOLIC ACID (IN PARTICULAR ITS PURIFICATION), WHICH IS A USEFUL DRUG FOR THE TREATMENT OR PREVENTION OF A DISEASE OR AFFECTION MEDIATED BY FXR, CARDIOVASCULAR OR COLESTRIAL COLES OR HESTS HDL, TO REDUCE TRIGLYCERIDES IN A MAMMER OR TO INHIBIT FIBROSIS.

CL2018001720A 2015-12-22 2018-06-22 Crystalline polymorphic forms of obetolic acid CL2018001720A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/979,005 US9982008B2 (en) 2012-06-19 2015-12-22 Preparation and uses of obeticholic acid

Publications (1)

Publication Number Publication Date
CL2018001720A1 true CL2018001720A1 (en) 2018-08-10

Family

ID=55650649

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001720A CL2018001720A1 (en) 2015-12-22 2018-06-22 Crystalline polymorphic forms of obetolic acid

Country Status (15)

Country Link
EP (1) EP3394081A1 (en)
JP (1) JP2018538331A (en)
KR (1) KR20180095070A (en)
CN (1) CN108495858A (en)
AU (1) AU2016375566A1 (en)
BR (1) BR112018012590A2 (en)
CA (1) CA3009149A1 (en)
CL (1) CL2018001720A1 (en)
CO (1) CO2018006701A2 (en)
EA (1) EA201891491A1 (en)
IL (1) IL259998A (en)
MX (1) MX2018007776A (en)
PH (1) PH12018501318A1 (en)
SG (1) SG11201805235XA (en)
WO (1) WO2017111979A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801653B (en) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 Crystal form A of shellfish cholic acid difficult to understand and preparation method thereof
WO2018211413A1 (en) * 2017-05-15 2018-11-22 Dr. Reddy’S Laboratories Limited Solid forms of obeticholic acid and process for preparation
CN109280071A (en) * 2017-07-19 2019-01-29 东莞东阳光药物研发有限公司 The crystal form and preparation method thereof of shellfish cholic acid difficult to understand
CN107383139A (en) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 The method that a kind of β cholanic acid new derivatives of 7 oxo of 3 α hydroxyls 5 prepare shellfish cholic acid difficult to understand
CZ31099U1 (en) * 2017-09-05 2017-10-17 Zentiva, K.S. The crystalline forms of (3α,5β,6α,7α)-6-ethyl-3,7-dihydroxycholan-24-oic acid
CN109485687A (en) * 2017-09-12 2019-03-19 成都弘达药业有限公司 The crystal form J and preparation method thereof of shellfish cholic acid difficult to understand
WO2019106043A1 (en) 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN113264972A (en) * 2020-02-14 2021-08-17 四川科伦药物研究院有限公司 Method for preparing obeticholic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050912A1 (en) * 2005-05-19 2006-11-20 Erregierre Spa PROCESS OF PREPARATION OF ACIDS 3-A-YA (B) -DIDROSSI-6-A (B) -ALCHIL-5B-COLANICI
US9238673B2 (en) * 2012-06-19 2016-01-19 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
CN106459136B (en) * 2014-09-28 2018-06-26 江苏盛迪医药有限公司 A kind of preparation method of Austria's shellfish cholic acid
KR102526632B1 (en) * 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
CN107207558B (en) * 2014-11-19 2019-10-29 Nzp英国有限公司 6 alpha-alkyl -6,7- diketone the steroids as the intermediate for preparing steroids FXR regulator
ES2748692T3 (en) * 2014-11-19 2020-03-17 Nzp Uk Ltd 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroid FXR modulators
EP3221331B1 (en) * 2014-11-19 2019-09-18 Nzp Uk Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators

Also Published As

Publication number Publication date
MX2018007776A (en) 2018-08-09
CO2018006701A2 (en) 2018-07-10
EP3394081A1 (en) 2018-10-31
PH12018501318A1 (en) 2019-02-18
CN108495858A (en) 2018-09-04
CA3009149A1 (en) 2017-06-29
SG11201805235XA (en) 2018-07-30
KR20180095070A (en) 2018-08-24
JP2018538331A (en) 2018-12-27
IL259998A (en) 2018-07-31
BR112018012590A2 (en) 2018-12-04
EA201891491A1 (en) 2018-11-30
AU2016375566A1 (en) 2018-07-05
WO2017111979A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
CL2018001720A1 (en) Crystalline polymorphic forms of obetolic acid
CO2017001884A2 (en) Polymorphs of selinexor
CL2020002277A1 (en) Crystalline forms of triazolopyrimidine compound (divisional 201803734)
DOP2017000149A (en) TRIAZOLOPIRIMIDINE COMPOUNDS AND USES OF THE SAME
CL2018001230A1 (en) Osteoarthritis treatment
CU24411B1 (en) COMPOSITE DERIVED FROM BENZAMIDE REPLACED WITH 1,3-TIAZOL-2-ILO USEFUL FOR THE TREATMENT OF NEUROGENIC DISORDERS
DOP2021000179A (en) SUBSTITUTE 5-FLUORO-1H-PYRAZOLOPYRIDINES PREPARATION PROCEDURE
CL2015002145A1 (en) Preparation, uses and solid forms of obetolic acid (divisional application No. 3475-2014)
ECSP17046848A (en) NEW COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND OSTEOARTHRITIS
FR3023286B1 (en) PROCESS FOR THE PRODUCTION OF TETRAFLUOROPROPENE
CL2018000914A1 (en) Compuestos derivados del acido (s)-3-amino-4-ciclopent-1-en-1-carboxilico, inactivadores de gaba aminotransferasa; composicion farmaceutica; metodo de tratamiento de trastornos psicologicos, neurologicos, adicciones, carcinoma hepatocelular, entre otras.
FR3024465B1 (en) CHARACTERIZATION OF MICROORGANISMS BY MALDI-TOF
CU20160003A7 (en) PIRAZOLOLPIRIDINAMINAS REPLACED
CL2018000962A1 (en) Opportunities for the recovery increase process as applied to molybdenum production
DK3305754T3 (en) Processes for the production of high-purity high-saturated fatty acid with high yield
BR112016017087A8 (en) alpha crystalline form of the monobenzoate compound a and its method of preparation and pharmaceutical composition comprising it
ES2967074T3 (en) 1 methylnicotinamide for the treatment of cardiovascular disease
FR3009555B1 (en) PROCESS FOR THE PREPARATION OF ORGANIC PEROXIDES
FI20156006A (en) Selective method for the conversion of levulinic acid to gamma valerolactone
DK3216780T3 (en) Process for the preparation of organic fluoride-aliphatic compound and process for the purification of organic fluoride-aliphatic compound
ES2689371A8 (en) Procedure for the preparation of pyrvinium pamoate and its crystalline forms
FR3039150B1 (en) PROCESS FOR THE PRODUCTION OF 5-HYDROXYMETHYLFURFURAL IN THE PRESENCE OF ORGANIC CATALYSTS OF THE THIOURE FAMILY
CL2016000498A1 (en) Process for the production of lactate.
DK3145553T3 (en) LITTLE INTERFERRING RNA (SIRNA) FOR TREATMENT OF TYPE 2 (ADO2) AUTOSOMAL DOMINANT OSTEOPETROSE CAUSED BY CLCN7 (ADO2 CLCN7 DEPENDENT) GENUTATION
GB201616500D0 (en) Biological process for the conversion of xylans to xylitol